Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET) (SABR-COMET)
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
This PHASE2 trial investigates Metastatic Tumors and is currently ongoing. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's leads this study, which shows 11 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
May 2022 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- London Regional Cancer Program, Canada
- VU University of Amsterdam
For direct contact, visit the study record on ClinicalTrials.gov .